Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Giannoukakis

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|October 2, 2007
BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analogNick Giannoukakis
Idrugs : the Investigational Drugs Journal|June 12, 2003
NBI-6024 (Neurocrine Biosciences)Nick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|November 8, 2006
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complicationsNick Giannoukakis
Biotechniques|July 18, 2003
Gene therapy technology applied to disorders of glucose metabolism: promise, achievements, and prospectsNick Giannoukakis, Massimo Trucco
Current Opinion in Molecular Therapeutics|October 27, 2005
Gene therapy for type 1 diabetes: a proposal to move to the next levelNick Giannoukakis, Massimo Trucco
Reviews in Endocrine & Metabolic Disorders|November 18, 2003
Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitusNick Giannoukakis, Massimo Trucco
Pediatric Diabetes|February 6, 2015
Cellular therapies based on stem cells and their insulin-producing surrogates: a 2015 reality checkNick Giannoukakis, Massimo Trucco
Current Opinion in Endocrinology, Diabetes, and Obesity|July 5, 2012
A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitusNick Giannoukakis, Massimo Trucco
Immunotherapy|November 15, 2012
Dendritic cell therapy for Type 1 diabetes suppressionNick Giannoukakis, Massimo Trucco
Expert Opinion on Biological Therapy|August 2, 2007
Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitusMassimo Trucco, Nick Giannoukakis
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Current Opinion in Investigational Drugs (London, England : 2000)|October 2, 2007
BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analogNick Giannoukakis
Idrugs : the Investigational Drugs Journal|June 12, 2003
NBI-6024 (Neurocrine Biosciences)Nick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|November 8, 2006
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complicationsNick Giannoukakis
Biotechniques|July 18, 2003
Gene therapy technology applied to disorders of glucose metabolism: promise, achievements, and prospectsNick Giannoukakis, Massimo Trucco
Current Opinion in Molecular Therapeutics|October 27, 2005
Gene therapy for type 1 diabetes: a proposal to move to the next levelNick Giannoukakis, Massimo Trucco
Reviews in Endocrine & Metabolic Disorders|November 18, 2003
Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitusNick Giannoukakis, Massimo Trucco
Pediatric Diabetes|February 6, 2015
Cellular therapies based on stem cells and their insulin-producing surrogates: a 2015 reality checkNick Giannoukakis, Massimo Trucco
Current Opinion in Endocrinology, Diabetes, and Obesity|July 5, 2012
A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitusNick Giannoukakis, Massimo Trucco
Immunotherapy|November 15, 2012
Dendritic cell therapy for Type 1 diabetes suppressionNick Giannoukakis, Massimo Trucco
Expert Opinion on Biological Therapy|August 2, 2007
Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitusMassimo Trucco, Nick Giannoukakis
Pageof 8